Scenarios that move ILMN

Illumina, Inc. - Common Stock

Scenarios that move ILMN: 2 analyses, 2 positive, 0 negative.

1. 2026-10-13 · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +20 · confidence low · horizon weeks
2. 2026-09-14 · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +10 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing